Myositis ossificans progressiva, left toe(s)
ICD-10 M61.178 is a billable code used to indicate a diagnosis of myositis ossificans progressiva, left toe(s).
Myositis ossificans progressiva (MOP) is a rare genetic disorder characterized by the abnormal formation of bone in muscles and connective tissues. This condition typically manifests in early childhood and progresses over time, leading to significant muscle stiffness and weakness. In the case of M61.178, the ossification specifically affects the left toe(s), which can result in pain, limited mobility, and functional impairment. The underlying pathophysiology involves mutations in the ACVR1 gene, which plays a crucial role in bone morphogenetic protein (BMP) signaling. Patients may experience episodes of soft tissue swelling followed by the development of heterotopic ossification, where bone forms in areas where it normally does not exist. Diagnosis is often confirmed through imaging studies, such as X-rays or MRI, which reveal the presence of abnormal bone formation. Management typically focuses on symptomatic relief, physical therapy, and avoiding trauma to affected areas to prevent exacerbation of the condition.
Detailed clinical notes on symptoms, family history, and genetic testing results.
Patients presenting with progressive muscle weakness and stiffness, particularly in the extremities.
Rheumatologists should be aware of the genetic basis of the condition and document any relevant family history.
Comprehensive genetic testing results and family pedigree charts.
Patients with a family history of myositis ossificans or unexplained muscle ossification.
Geneticists must ensure that the documentation clearly links the genetic findings to the clinical diagnosis.
Used for follow-up visits for management of myositis ossificans.
Detailed notes on patient history, examination findings, and treatment plan.
Rheumatologists should document the progression of symptoms and response to therapy.
Myositis ossificans progressiva is a rare genetic disorder characterized by the abnormal formation of bone in muscles and connective tissues, leading to progressive stiffness and weakness.
Diagnosis is primarily clinical, supported by imaging studies that reveal abnormal bone formation, and can be confirmed through genetic testing for ACVR1 mutations.
